Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting

Ads

You May Also Like

ThromboGenics Business Update – H1 2017

Press release                                                          7 September, 2017Regulated Information Good Progress in Advancing Diabetic Eye Disease Portfolio ...